Harpoon Therapeutics Inc - Ordinary Shares
News
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Merck & Co., Inc. Acquires 21,397,205 Shares
Zolmax Harpoon Therapeutics, Inc. (NASDAQ:HARP Get Free Report) major shareholder Merck & Co., Inc. purchased 21,397,205 shares of the companys stock in a transaction that occurred on Monday...\n more…
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago. These figures are adjusted...\n more…
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Business Wire Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned...\n more…
Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck
Seeking Alpha - Healthcare Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck...\n more…
